DEA Classifies Tramadol as a Schedule IV Controlled Substance

Krystle Vermes
Published Online: Thursday, August 21, 2014
Follow Pharmacy_Times:
As of August 18, 2014, the Drug Enforcement Administration (DEA) has officially placed tramadol, a centrally acting opioid analgesic, into schedule IV of the Controlled Substances Act.
 
In the past, it was widely believed that tramadol had a better safety profile than other opioid analgesics. Now that the drug has been deemed a Schedule IV substance, however, health care professionals may be less likely to prescribe it to patients for pain.
 
Within the first 2 years of the drug’s approval for use in the United States, between 2 to 3 patients out of every 100,000 were abusing tramadol, experts found. Researchers also discovered that patients were susceptible to suffering from opioid-like withdrawal symptoms after stopping tramadol treatment. In fact, 40% of the adverse effects associated with tramadol are linked to discontinuation of the painkiller.
 
In 2010 alone, more than 16,000 visits to the emergency room were documented as resulting from the use of tramadol for non-medial purposes.
 
This past June, the United Kingdom decided to place tramadol under strict restrictions. Several states have been implementing laws of their own to schedule tramadol as a controlled substance. As a result, the level of exposure to the drug has dropped in those areas.
 
Now that the DEA has stepped in, there is potential for the amount of tramadol exposure to decrease across the nation as a whole.
 
“As confirmed by the association, current distributors of tramadol are DEA registrants with existing controlled substance storage that complies with DEA regulations,” the agency explained in its declaration. “The DEA understands that handlers of tramadol may need to make modifications to their current security procedures for compliance. These modifications necessary for security compliance will be a 1-time modification to provide for the appropriate storage, revision of operating procedures, training of staff, and amendments to suspicious order monitoring systems to include customer verifications.”
Related Articles
A drug therapy for epilepsy and shingles pain is being voluntarily recalled by its manufacturer due to complaints of empty capsules.
Several provisions of the Affordable Care Act intend to improve smoking cessation rates by increasing insurance coverage for effective interventions.
The FDA today approved hydrocodone bitartrate, an extended-release opioid analgesic for treating severe pain that requires daily long-term opioid treatment and for which other treatment options are inadequate.
A diverse collective of health care advocacy groups, patient organizations, industry representatives and other stakeholders today announced they have established the Alliance for Balanced Pain Management to support appropriate access to integrated pain management and responsible use of prescription pain medicines with an aim to reduce abuse. AfBPM will work collaboratively to educate, support and advocate on behalf of people affected by pain, both acute and chronic.
Latest Issues
$auto_registration$